Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Lumb
Alistair N
AN
Gallen
Ian W
IW
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism*; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008875:Middle Aged; D000077205:Pioglitazone; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*; D000077154:Rosiglitazone; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000627:therapeutic use; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D005907:Gliclazide; D006442:Glycated Hemoglobin; D051538:Hepatocyte Nuclear Factor 1-alpha; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D011719:Pyrazines; D000077154:Rosiglitazone; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones; D014230:Triazoles